Recent News

• 06.10.2025 - Goldman Sachs Global Healthcare Conference
• 06.03.2025 - Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
• 06.03.2025 - Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
• 06.01.2025 - Bicara Therapeutics ASCO Data Call
• 06.01.2025 - ASCO 2025: Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: Updated results from an expansion cohort of an open-label, multicenter, phase 1/1b trial
• 06.01.2025 - Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
• 06.01.2025 - Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
• 05.22.2025 - Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
• 05.22.2025 - Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
• 05.13.2025 - Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 05.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 8-K Current report
• 05.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors